<?xml version='1.0' encoding='utf-8'?>
<?xml-stylesheet type="text/xsl" href="/v2/static/oai2.xsl"?>
<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2026-10-11T19:46:59Z</responseDate>
  <request identifier="oai:figshare.com:article/33992074" metadataPrefix="oai_dc" verb="GetRecord">https://api.figshare.com/v2/oai</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:figshare.com:article/33992074</identifier>
        <datestamp>2026-09-25T04:25:59Z</datestamp>
        <setSpec>category_388</setSpec>
        <setSpec>portal_316</setSpec>
        <setSpec>item_type_3</setSpec>
        <setSpec>month_year_09_2026</setSpec>
      </header>
      <metadata>
        <oai_dc:dc xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"  xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:title>Table 1_CT-based deep learning auto-segmentation of high-risk clinical target volume in CT-guided cervical cancer brachytherapy: a single-center pragmatic study.doc</dc:title>
          <dc:creator>Chen-ying Ma (24234966)</dc:creator>
          <dc:creator>Yi Fu (315254)</dc:creator>
          <dc:creator>Lu Zhang (50563)</dc:creator>
          <dc:creator>Lou Liu (24234960)</dc:creator>
          <dc:creator>Yu Wang (12152)</dc:creator>
          <dc:creator>Le-cheng Jia (25107115)</dc:creator>
          <dc:creator>Wei-qi Xiong (25107118)</dc:creator>
          <dc:creator>Wei Zhang (405)</dc:creator>
          <dc:creator>Xiao-ting Xu (14650523)</dc:creator>
          <dc:creator>Ju-ying Zhou (24234963)</dc:creator>
          <dc:subject>Oncology and Carcinogenesis not elsewhere classified</dc:subject>
          <dc:subject>automated segmentation</dc:subject>
          <dc:subject>brachytherapy</dc:subject>
          <dc:subject>cervical cancer</dc:subject>
          <dc:subject>CT-guided workflow</dc:subject>
          <dc:subject>deep learning</dc:subject>
          <dc:subject>high-risk clinical target volume</dc:subject>
          <dc:description>Introduction&lt;p&gt;Computed tomography (CT)-based high-risk clinical target volume (HR-CTV) auto-segmentation has been previously investigated, but evidence remains heterogeneous across applicators, target definitions, architectures, and clinical evaluation procedures. A pragmatic within-cohort benchmark of 2D U-Net, 3D U-Net, and nnFormer was performed in a CT-only, applicator-in-situ workflow.&lt;/p&gt;Methods&lt;p&gt;CT images from 544 brachytherapy fractions in 182 patients were analyzed, including 509 fractions from 163 patients treated with tandem-and-ovoid applicators and 35 fractions from 19 patients treated with vaginal cylinders. All fractions from a patient remained in one partition (HR-CTV&lt;sub&gt;c&lt;/sub&gt;: 325/82/102 fractions; HR-CTV&lt;sub&gt;v&lt;/sub&gt;: 22/6/7 fractions). Only seven test fractions were available and thus the postoperative HR-CTV&lt;sub&gt;v&lt;/sub&gt; analysis was exploratory. Performance was assessed using Dice similarity coefficient (DSC), 95th percentile Hausdorff distance (HD95), average surface distance (ASD), and physician consensus edit categories. Task-level CT normalization parameters were estimated exclusively from the training partition and fixed for validation and testing; spatial cropping was image centered and contour independent.&lt;/p&gt;Results&lt;p&gt;In the intact-cervix test cohort, 3D U-Net showed the most favorable descriptive combination of overlap and surface agreement (DSC 0.848 ± 0.059; HD95 2.755 ± 1.688 mm; ASD 1.008 ± 0.622 mm). In the exploratory vaginal stump cohort, corresponding values were 0.788 ± 0.060, 4.724 ± 2.434 mm, and 2.917 ± 2.150 mm. On physician consensus review, 91/102 HR-CTV&lt;sub&gt;c&lt;/sub&gt; and 6/7 HR-CTV&lt;sub&gt;v&lt;/sub&gt; 3D U-Net contours required no or localized correction. In an ancillary 20-fraction independent-contouring analysis, physician-to-physician HR-CTV agreement was DSC 0.80 ± 0.06 and HD95 3.4 ± 1.8 mm.&lt;/p&gt;Conclusions&lt;p&gt;In this internally validated CT-guided cohort, 3D U-Net provided the most favorable overall performance among the evaluated architectures for intact-cervix cases. The postoperative results provide a preliminary feasibility signal, and confirmation in a larger cohort is required. These findings support further physician-supervised implementation, followed by multicenter external validation and cohort-level dosimetric assessment.&lt;/p&gt;</dc:description>
          <dc:date>2026-09-25T04:25:59Z</dc:date>
          <dc:type>Dataset</dc:type>
          <dc:type>Dataset</dc:type>
          <dc:identifier>10.3389/fonc.2026.1936913.s001</dc:identifier>
          <dc:relation>https://figshare.com/articles/dataset/Table_1_CT-based_deep_learning_auto-segmentation_of_high-risk_clinical_target_volume_in_CT-guided_cervical_cancer_brachytherapy_a_single-center_pragmatic_study_doc/33992074</dc:relation>
          <dc:rights>CC BY 4.0</dc:rights>
        </oai_dc:dc>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
